Appeals court backs Ortho-McNeil in Topamax fight
WASHINGTON, March 31 (Reuters) - A federal appeals court on Monday upheld a ruling that prevents generic drug maker Mylan MYL.N from pursuing efforts to market a version of the epilepsy drug Topamax until Ortho-McNeil Pharmaceutical Inc's patent expires.
The U.S. Court of Appeals for the Federal Circuit found that a District Court in New Jersey district was correct in siding with Ortho-McNeil, a unit of Johnson & Johnson (JNJ.N).
Ortho-McNeil said on its web site that the Topamax patent expires in September.
Under the Hatch-Waxman Act to encourage generic versions of drugs to be marketed quickly after a patent expires, Mylan had filed an application with the Food and Drug Administration saying it intended to bring out a version of Topamax. As part of that application, Mylan said Ortho-McNeil's patent was invalid.
But Ortho-McNeil disagreed, and filed a lawsuit saying its patent rights had been infringed. (Reporting by Diane Bartz; Editing by Tim Dobbyn)
© Thomson Reuters 2009 All rights reserved
Green Shoots / Brown Weeds
Jobless claims drop steeply
The number of U.S. workers filing new claims for jobless benefits fell sharply last week, although the data was distorted by an unusual pattern of layoffs in the automotive industry. Full Article
Bad weather hurts retail sales
Sales fell at many U.S. apparel retailers and warehouse club stores in June as the weak economy and cool, rainy weather dashed interest in summer shopping for consumers across the country. Full Article
